Eckert & Ziegler Strahlen- und Medizintechnik AG

Legal Proceedings Report • Feb 18, 2008

News Details

Ad-hoc | 18 February 2008 18:32

Eckert & Ziegler and IBt to consolidate their activities in the brachytherapy area

ECKERT & ZIEGLER Strahlen- und Medizintechnik AG / Letter of Intent

Release of an Ad hoc announcement according to § 15 WpHG, transmitted by
DGAP - a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.

---

Berlin, 18.02.2008 - Eckert & Ziegler AG, a specialist for medical
isotopes, today signed a Letter of Intent with Belgian medical device
company International Brachytherapy SA (IBt) about the consolidation of
their respective implant businesses. For this purpose of this
consolidation, Eckert & Ziegler will transfer the shares of it’s subsidiary
Eckert & Ziegler BEBIG GmbH, which contains the implant business, against
shares of IBt that are issued through a capital increase. In addition,
Eckert & Ziegler grants IBt the option to later also purchase the reminder
of its therapy business.

The implant business of Eckert & Ziegler, according to preliminary figures,
in 2007 had revenues of roughly 10 Mio. EUR and an EBITDA of 3.9 Mio. EUR.
The remaining parts of the therapy segment of Eckert & Ziegler had revenues
of approximately 12 Mio. EUR.

Also part of the agreement is an option, given by the founders of IBt to
EZAG, about the transfer of so called 'IBt Beneficiary Shares' that the
founders currently hold. The Beneficiary Shares offer no direct economic
benefit, but carry voting rights in the share holder meeting of IBt. Eckert
& Ziegler will be able to acquire these rights in exchange for
approximately 1 Mio. EUR in treasury shares of Eckert & Ziegler.

Should Eckert & Ziegler exercise the option to acquire the Beneficiary
Shares, it would need to submit amendatory take over bit to the other share
holders of IBt.

More details about the transaction and background can be found in the press
release that has been put into the websites of Eckert & Ziegler and IBt.

The Executive Board

For enquiries please contact:
Eckert & Ziegler AG, Thomas Scheuch, Investor Relations
Robert-Rössle-Str. 10, D-13125 Berlin
Tel.: +49 (0) 30 / 94 10 84-139, Fax -112, E-mail: thomas.scheuch@ezag.de,
www.ezag.de

18.02.2008 Financial News transmitted by DGAP

Language: English
Issuer: ECKERT & ZIEGLER Strahlen- und Medizintechnik AG
Robert-Rössle-Str. 10
13125 Berlin
Deutschland
Phone: +49 (0)30 941 084-0
Fax: +49 (0)30 941 084-112
E-mail: thomas.scheuch@ezag.de
Internet: www.ezag.de
ISIN: DE0005659700
WKN: 565970
Listed: Regulierter Markt in Frankfurt (Prime Standard), Stuttgart;
Freiverkehr in Berlin, München, Hamburg, Düsseldorf

End of News DGAP News-Service

---